The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia;Działanie przeciwzapalne i antyoksydacyjne zmikronizowanego fenofibratu u chorych z otyłościa̧ brzuszna̧ i dyslipidemia̧

Polski Merkuriusz Lekarski

Volumn 20, Issue 119, 2006, Pages 547-550

  Broncel, Marlena ^a   Cieślak, Dorota ^a   Koter Michalak, Maria ^a   Duchnowicz, Piotr ^a   Mackiewicz, Katarzyna ^a   Chojnowska Jezierska, Julita ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antioxidative enzymes; Dyslipidemia; Fenofibrate; Inflammation; Obesity

Indexed keywords

C REACTIVE PROTEIN; CATALASE; FENOFIBRATE; FIBRINOGEN; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; FEMALE; FIBRINOLYSIS; GLUCOSE METABOLISM; HUMAN; HYPOLIPEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; THROMBOSIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; C-REACTIVE PROTEIN; DYSLIPIDEMIAS; ERYTHROCYTE MEMBRANE; FEMALE; FENOFIBRATE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; OBESITY; PROCETOFEN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 33744481800     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Arnaiz S.L., Travacio M., Llesuy S.B. i wsp.: Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim. Biophys. Acta, 1995, 1272, 175-180.
2. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. i wsp.: Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism, 2005, 54, 1065-1074.
3. Bairaktari E.T., Tzallas C.S., Tsimihodimos V.K. i wsp.: Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J. Cardiovasc. Risk, 1999, 6, 113-116.
4. Barbier O., Torra I.P., Duguay Y. i wsp.: Pleiotropic actions of peroxisome proliferators-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Tromb. Vasc. Biol., 2002, 22, 717-726.
5. +2-ATPase by membrane disturbing agents. Biochem. Mol. Biol. Int., 1994, 34, 521-529.
6. Bełtowski J., Wójcicka G., Mydlarczyk M. i wsp.: The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity. J. Physiol. Pharmacol., 2002, 53, 463-475.
7. Branchi A., Rovellini A., Sommariva D. i wsp.: Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb. Haemost., 1993, 70, 241-243.
8. Broda G., Szcześniewska D., Rywik S.: Czȩstoś ć wystȩpowania zespołu metabolicznego w populacji osób dorosłych Warszawy. Med. Metab., 2003, 7, 25-29.
9. Coban E., Ozdogan M., Yazicioglu G. i wsp.: The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic hypertensive patients. Int. J. Clin. Pract., 2005, 59, 415-418.
10. Colak E.: Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. 2005, 37, 613-620.
11. Despres J.P., Lemieux I., Pascot A. i wsp.: Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with atherogenic dyslipidemia of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 702-703.
12. Dodge J.T., Mitchel C., Hanahan D.J.: The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys., 1963, 100, 119-130.
13. Ferretti G., Bacchetti T., Busni D. i wsp.: Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab., 2004, 89, 2957-2962.
14. Frost R.J., Otto C., Geiss H.C. i wsp.: Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol., 2001, 87, 44-48.
15. van Gaal L.F., Vertommen J., De Leeuw I.H.: The in vitro oxidizability of lipoprotein in obese and non-obese subjects. Atherosclerosis, 1998, 137, suppl. 39-44.
16. Isomaa B., Almgren P., Tuomi T. i wsp.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24, 683-689.
17. Jayakumari N., Ambikakumari V., Balakrishnan K.G. i wsp.: Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis, 1992, 94, 183-190.
18. Jonkers I.J., Mohrschladt M.F., Westendorp R.G. i wsp.: Severe hypertriglycerydemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled study. Am. J. Med., 2002, 112, 275-280.
19. Klucis E., Crane E., Master C. i wsp.: Sequential alterations in the microlocalization of catalase in mouse liver after treatment with hypolipidemic drugs. Mol. Cell Bioch., 1984, 65, 73-82.
20. Kockx M., Gervois P.P., Poulain P. i wsp.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferators activated receptor α. Blood, 1999, 93, 2991-2998.
21. Kowalski J., Błaszczyk J., Olejniczak J. i wsp.: Wpływ fluwastatyny i fenofibratu na wytwarzanie reaktywnych form tlenu i peroksydacjȩ lipidów u chorych z dyslipidemia̧. Pol. Merk. Lek., 2003, 14, 279-284.
22. Kowalski J., Olejniczak J., Błaszczyk J. i wsp.: Wpływ fluwastatyny i fenofibratu na aktywność enzymów bariery antyoksydacyjnej u chorych z dyslipidemia̧. Pol. Merk. Lek., 2003, 14, 285-288.
23. Maison P., Mennen L., Sapinho D. i wsp.: A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atheroslcerosis, 2002, 160, 155-160.
24. Melenovsky V., Malik J., Wichterle D. i wsp.: Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart J., 2002, 144, 6.
25. Misra M.P.: Handbook of methods for oxygen radical research. Boca Raton, 1985.
26. Okopień B., Cwalina L., Lebek M. i wsp.: Effects of fibrates on plasma prothrombic activity in patients with type IIb dyslipidemia. Int. J. Clin. Pharmacol. Ther., 2001, 39, 551-557.
27. Okopień B., Haberka M., Sierant M.: Plejotropowe działanie inhibitorów konwertazy angiotensyny i fibratów. Kardiol. Pol., 2005, 62, suppl. 2, 65-68.
28. Rice-Evans C.A., Daglock A., Svmonts M.C.R.: Techniques in free radical research. Elsevier. Amsterdam. 1991.
29. Rizos E., Kostoula A., Elisaf M. i wsp.: Effect of ciprofibrate on C-reactive protein and fibrynogen levels. Angiology, 2002, 53, 273-277.
30. Sebestjen M., Keber I., Zegura B. i wsp.: Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb. Haemost., 2004, 92, 1129-1135.
31. Skrha J., Stulc T., Hilgertova J. i wsp.: Effecf of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur. J. Pharmacol., 2004, 493, 183-189.
32. Steinmetz A., Schwartz T., Hehnke U. i wsp.: Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipoproteinemia. J. Cardiovasc. Pharmacol., 1996, 27, 563-570.
33. de la Serna G., Cadaraso C.: Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin. Pharmacol. Ther., 1999, 66, 166-172.
34. Simon E., Paul J.L., Alger V., Simon A. i wsp.: Erythrocyte antioxidants status in asymptomatic hypercholesterolemic men. Atherosclerosis, 1998, 138, 375-381.
35. Stocks J., Dormandy T.L.: The autooxidation of red cell lipids induced by hydrogen peroxide. Br. J. Haematol., 1971, 20, 95-111.
36. Undas A., Celinska-Lowenhoff M., Domagala T.B. i wsp.: Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb. Haemost., 2005, 94, 193-199.
37. Vu-Dac N., Schoonjans K., Laine B. i wsp.: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferators-activated receptor with its response element. J. Biol. Chem., 1994, 269, 31012-31018.
38. Wang T.D., Chen W.J., Lin J.W. i wsp.: Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis, 2003, 170, 315-323.
39. Yesilbursa D., Serdar A., Saltan Y. i wsp.: The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol. Pol., 2005, 62, 526-529.